Press release
February 26, 2015

New edition of AMINONews® is out

Threonine, an essential amino acid, is not only a building block in meat production but has also a key function in the metabolism of the intestine and in immune responses. The current knowledge about this subject and the consequences for an ideal amino acid profile of pigfeed is explained by Dr. John Htoo in the latest edition of Evonik's customer magazine AMINONews® for the feed industry.

Amino acid supplementation is also catching on in aquaculture. But how to define a species' amino acid requirements? Dr. Andreas Lemme provides an insight into test approaches for tilapia feeding. As the results show, the optimum methionine concentration for this African cichlid fish is significantly above current recommendations.

New approaches to animal nutrition also come along with new findings on the topic of oxidative stress. Dr. Behnam Saremi summarizes the basic mechanisms for the latest AMINONews®.

Brief information on other current developments and scientific publications in the field of amino acids in animal nutrition round off the selection of topics in this latest edition of Evonik's customer magazine. It is published in five languages: English, German, Spanish, Russian, and Chinese.

Evonik is the only company in the world that produces and markets all four essential amino acids used in advanced animal nutrition: MetAMINO® (DL-methionine), Biolys® (L-lysine source), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). Mepron®, a rumen-stable DL-methionine for high-performance dairy cows, and CreAMINO®, a creatine source for broilers complement the product portfolio. The company markets innovative products and services in more than one hundred countries and thus makes a valuable contribution to the cost-efficiency of its customers and to healthy and environment-friendly animal nutrition.

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.